{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE338nnn/GSE338233/"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Transcriptomics"],"species":["Homo sapiens"],"gds_type":["Expression profiling by high throughput sequencing"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE338233"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"Transcriptomic profiling of MIA PaCa-2 cells treated with hydroxyprogesterone caproate","description":"Pancreatic ductal adenocarcinoma (PDAC) remains refractory to targeted therapy. This RNA-sequencing study characterizes transcriptional changes in the human PDAC cell line MIA PaCa-2 following treatment with hydroxyprogesterone caproate (HPC). Comparison with DMSO vehicle-treated cells was used to identify HPC-responsive genes and pathways. The transcriptomic analysis supported repression of cell-cycle, DNA-replication and pyrimidine-metabolism programs and contributed to investigation of the COP1-CEBPB-CDA mechanism underlying the anti-PDAC activity of HPC.","dates":{"publication":"2026/07/11"},"accession":"GSE338233","cross_references":{"GSM":["GSM9869673","GSM9869672","GSM9869671","GSM9869670","GSM9869679","GSM9869678","GSM9869677","GSM9869676","GSM9869675","GSM9869674"],"GPL":["24676"],"GSE":["338233"],"taxon":["Homo sapiens"]}}